null

Durvalumab Biosimilar (Anti-PDL1) Antibody (HDBS0133)

SKU:
HDBS0133
Antibody Type:
Biosimilar Reference Antibody
Applications:
IHC
FC
Drug Development
Pharmacokinetics
Disease Area:
Cancer
Protein:
PD-L1
Reactivity:
Human
Host Species:
Humanized
Isotype:
IgG1
$479

Description

system_update_altDatasheet

Durvalumab (Anti-PDL1) Biosimilar Antibody (HDBS0133)

The Durvalumab Biosimilar Anti-PD-L1 Antibody is a cutting-edge therapeutic antibody designed for research and potentially clinical applications. This biosimilar antibody targets the PD-L1 protein, a critical immune checkpoint molecule that helps cancer cells evade the immune system. By blocking PD-L1, Durvalumab enhances the immune response against cancer cells, making it a promising tool in cancer immunotherapy.This antibody is highly specific for PD-L1 and has been validated for use in various experimental settings, including flow cytometry, immunohistochemistry, and functional assays.

Its high affinity and potency make it an excellent choice for studying PD-L1 expression and function in cancer cells and tumor microenvironments.Overall, the Durvalumab Biosimilar Anti-PD-L1 Antibody is a valuable tool for researchers studying cancer immunology and exploring new strategies for cancer therapy. Its potential as a therapeutic agent in the treatment of various cancer types makes it a promising candidate for further development and investigation.